Recruiting Clinical Trials

Displaying 21 - 30 of 242 result(s)
Study Title Condition Phase Location
An Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Prostatic Neoplasms Phase 3
  • Country: 
    United States
  • Country: 
    Austria
  • Country: 
    Belgium
  • Country: 
PSMAfore: A Phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in the Treatment of Taxane Naïve Men With Progressive Metastatic Castrate Resistant Prostate Cancer Prostatic Neoplasms Phase 3
  • Country: 
    United States
  • Country: 
    Austria
  • Country: 
    Belgium
  • Country: 
Regulatory Post-Marketing Surveillance (rPMS) Study for Brolucizumab(Beovu ® Injection, Beovu ®Prefilled Syringe) Neovascular Age-related Macular Degeneration Not Given
  • Country: 
    Korea, Republic of
A Phase Ib Dose Finding Study Assessing Safety and Activity of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Extensive Stage Small Cell Lung Cancer (ES-SCLC) in Combination With Carboplatin, Etoposide and Tislelizumab in Induction and With Tislelizumab in M ... Extensive Stage Small Cell Lung Cancer Phase 1
  • Country: 
    France
Open-Label Rater-Blind Randomized Multi-Center Parallel-Arm Active- Comparator Study to Assess the Efficacy and Tolerability of Ofatumumab 20mg SC Monthly vs. First Line DMT - Physician's Choice in the Treatment of Newly Diagnosed RMS Multiple Sclerosis Phase 3
  • Country: 
    France
  • Country: 
    Germany
  • Country: 
    Italy
  • Country: 
A 2-year Randomized, 3-arm, Double-blind, Non-inferiority Study Comparing the Efficacy and Safety of Ofatumumab and Siponimod Versus Fingolimod in Pediatric Patients With Multiple Sclerosis Followed by an Open-label Extension Multiple Sclerosis (MS) Phase 3
  • Country: 
    United States
  • Country: 
    Australia
  • Country: 
    Austria
  • Country: 
Randomized, Single-dose, Open-label, Two-part, Two-period, Cross-over Study to Compare the Pharmacokinetics, Safety and Tolerability of the Pediatric With an Adult Formulation of Branaplam and to Investigate the Adult Formulation in Fed and Fasted St ... Healthy Volunteers Phase 1
  • Country: 
    United Kingdom
A Multicenter Open-label Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With Somatostatin Receptor Positive Gastroenteropancreatic Neuroendocrine (GEP-NET) Tumors, Pheochromocytoma and Paragangliomas (PPGL) Gastroenteropancreatic Neuroendocrine Tumors, Pheochromocytoma, Paraganglioma Phase 2
  • Country: 
    United States
  • Country: 
    Belgium
  • Country: 
    France
  • Country: 
A Randomized, Two-arm, Placebo-controlled, Participant and Investigator-blinded Study Investigating the Efficacy, Safety and Tolerability of DFV890 in Patients With Symptomatic Knee Osteoarthritis Symptomatic Knee Osteoarthritis Phase 2
  • Country: 
    United States
  • Country: 
    Argentina
  • Country: 
    Czech Republic
  • Country: 
A Phase I/Ib, Open-label, Multi-center, Study of NZV930 as a Single Agent and in Combination With PDR001 and/or NIR178 in Patients With Advanced Malignancies. Non-small Cell Lung Cancer (NSCLC), Triple Negative Breast Cancer (TNBC), Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer Microsatellite Stable (MSS), Ovarian Cancer, Renal Cell Carcinoma (RCC), Metastatic Castration Resistant Prostate Cancer (mCRPC) Phase 1
  • Country: 
    United States
  • Country: 
    Australia
  • Country: 
    Canada
  • Country: